Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis.

Vera-Badillo FE, Templeton AJ, Duran I, Ocana A, de Gouveia P, Aneja P, Knox JJ, Tannock IF, Escudier B, Amir E.

Eur Urol. 2015 Apr;67(4):740-9. doi: 10.1016/j.eururo.2014.05.010. Review.

PMID:
24882670
2.

Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.

Kroeger N, Pantuck AJ, Wells JC, Lawrence N, Broom R, Kim JJ, Srinivas S, Yim J, Bjarnason GA, Templeton A, Knox J, Bernstein E, Smoragiewicz M, Lee J, Rini BI, Vaishampayan UN, Wood LA, Beuselinck B, Donskov F, Choueiri TK, Heng DY.

Eur Urol. 2015 Sep;68(3):506-15. doi: 10.1016/j.eururo.2014.11.054.

PMID:
25524810
3.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Voss MH, Bastos DA, Karlo CA, Ajeti A, Hakimi AA, Feldman DR, Hsieh JJ, Molina AM, Patil S, Motzer RJ.

Ann Oncol. 2014 Mar;25(3):663-8. doi: 10.1093/annonc/mdt578.

4.

A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.

Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A.

Eur Urol. 2016 Dec 7. pii: S0302-2838(16)30853-3. doi: 10.1016/j.eururo.2016.11.020. [Epub ahead of print] Review.

PMID:
27939075
5.

Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.

Volpe A, Novara G, Antonelli A, Bertini R, Billia M, Carmignani G, Cunico SC, Longo N, Martignoni G, Minervini A, Mirone V, Simonato A, Terrone C, Zattoni F, Ficarra V; Surveillance and Treatment Update on Renal Neoplasms (SATURN) Project.; Leading Urological No-Profit Foundation for Advanced Research (LUNA) Foundation..

BJU Int. 2012 Jul;110(1):76-83. doi: 10.1111/j.1464-410X.2011.10690.x.

6.

Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.

Tirumani SH, Souza D, Krajewski KM, Jagannathan JP, Ramaiya NH, Shinagare AB.

Abdom Radiol (NY). 2016 Feb;41(2):295-302. doi: 10.1007/s00261-015-0569-7.

PMID:
26867911
7.

Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.

Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Tan MH, Bamias A, Kollmannsberger CK, North SA, Rini BI, Heng DY.

Eur Urol. 2014 Jun;65(6):1086-92. doi: 10.1016/j.eururo.2013.07.031.

PMID:
23916693
8.

Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.

Jiang HM, Wei JH, Zhang ZL, Fang Y, Zhou BF, Chen ZH, Lu J, Liao B, Zhou FJ, Luo JH, Chen W.

Int Urol Nephrol. 2016 Feb;48(2):191-9. doi: 10.1007/s11255-015-1161-3. Review.

PMID:
26589610
9.

Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria.

Kroeger N, Xie W, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T, Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DY.

Cancer. 2013 Aug 15;119(16):2999-3006. doi: 10.1002/cncr.28151.

10.

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK.

Eur Urol. 2016 May;69(5):866-74. doi: 10.1016/j.eururo.2015.10.049.

PMID:
26626617
11.

Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T, Donskov F, North SA, Heng DY, Rini BI.

Clin Genitourin Cancer. 2015 Apr;13(2):e79-85. doi: 10.1016/j.clgc.2014.08.011.

PMID:
25450036
12.

Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma.

Wu J, Caliendo G, Hu XP, Dutcher JP.

Med Oncol. 1998 Apr;15(1):44-9.

PMID:
9643530
13.

Sarcomatoid-variant renal cell carcinoma: treatment outcome and survival in advanced disease.

Molina AM, Tickoo SK, Ishill N, Trinos MJ, Schwartz LH, Patil S, Feldman DR, Reuter VE, Russo P, Motzer RJ.

Am J Clin Oncol. 2011 Oct;34(5):454-9. doi: 10.1097/COC.0b013e3181f47aa4.

14.

Targeted therapy for advanced renal cell carcinoma.

Coppin C, Le L, Porzsolt F, Wilt T.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006017. doi: 10.1002/14651858.CD006017.pub2. Review.

PMID:
18425931
15.

Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival.

Belsante M, Darwish O, Youssef R, Bagrodia A, Kapur P, Sagalowsky AI, Lotan Y, Margulis V.

Urol Oncol. 2014 Jan;32(1):30.e23-8. doi: 10.1016/j.urolonc.2012.11.002.

PMID:
23428539
16.

Three-dimensional tumour volume and cancer-specific survival for patients undergoing nephrectomy to treat pT1 clear-cell renal cell carcinoma.

Jorns J, Thiel DD, Lohse CM, Williams A, Arnold ML, Cheville JC, Leibovich BC, Parker AS.

BJU Int. 2012 Oct;110(7):956-60. doi: 10.1111/j.1464-410X.2012.10937.x.

18.

High cytoplasmic expression of p27(Kip1) is associated with a worse cancer-specific survival in clear cell renal cell carcinoma.

Kruck S, Merseburger AS, Hennenlotter J, Scharpf M, Eyrich C, Amend B, Sievert KD, Stenzl A, Bedke J.

BJU Int. 2012 May;109(10):1565-70. doi: 10.1111/j.1464-410X.2011.10649.x.

19.

The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma.

Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlbäck B.

Eur J Cancer. 2014 Jul;50(10):1758-65. doi: 10.1016/j.ejca.2014.03.281.

PMID:
24793999
20.

Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases.

de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB.

Am J Surg Pathol. 2001 Mar;25(3):275-84.

PMID:
11224597
Items per page

Supplemental Content

Support Center